Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential

Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

(2012) K Yoshida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions

(2012) Maria Karlgren et al.   JOURNAL OF MEDICINAL CHEMISTRY

In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine-Treated as Compared With Tacrolimus-Treated Renal Allograft Recipients

(2011) H de Jonge et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

(2011) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions

(2011) Maria Karlgren et al.   PHARMACEUTICAL RESEARCH

Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation

(2010) R. S. Foti et al.   DRUG METABOLISM AND DISPOSITION

Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin

(2010) R. Amundsen et al.   DRUG METABOLISM AND DISPOSITION

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

(2010) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

The effect ofSLCO1B1polymorphism on repaglinide pharmacokinetics persists over a wide dose range

(2008) Annikka Kalliokoski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Grapefruit Juice-Drug Interaction Studies as a Method to Assess the Extent of Intestinal Availability: Utility and Limitations

(2008) Michael Gertz et al.   CURRENT DRUG METABOLISM

Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION

Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

(2008) Annikka Kalliokoski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

(2008) Annikka Kalliokoski et al.   Pharmacogenetics and Genomics